Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats

Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats Continuous dopaminergic treatment is considered to prevent or delay the occurrence of dyskinesia in patients with Parkinson’s disease (PD). Rotigotine is a non-ergolinic D 3 > D 2 > D 1 dopamine-receptor agonist for the treatment of PD using a transdermal delivery system providing stable plasma levels. We aimed to investigate the differential influence on gene expression of pulsatile l -DOPA or rotigotine versus a continuous rotigotine treatment. The gene expression profile within the nigro-striatal system of unilateral 6-hydroxydopamine-lesioned rats was assessed in order to differentiate potential changes in gene expression following the various treatment using Affymetrix microarrays and quantitative RT-PCR. The expression of 15 genes in the substantia nigra and of 11 genes in the striatum was altered under pulsatile treatments inducing dyskinetic motor response, but was unchanged under continuous rotigotine treatment that did not cause dyskinetic motor response. The route of administration of a dopaminergic drug is important for the induction or prevention of motor abnormalities and adaptive gene expressions. The decline of neurotrophin-3 expression under pulsatile administration was considered of particular importance. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Neural Transmission Springer Journals

Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats

Loading next page...
 
/lp/springer-journals/transcriptional-alterations-under-continuous-or-pulsatile-dopaminergic-L6dt3ySHyU

References (32)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Psychiatry; Neurology; Pharmacology/Toxicology; Neurosciences
ISSN
0300-9564
eISSN
1435-1463
DOI
10.1007/s00702-010-0552-y
pmid
21188436
Publisher site
See Article on Publisher Site

Abstract

Continuous dopaminergic treatment is considered to prevent or delay the occurrence of dyskinesia in patients with Parkinson’s disease (PD). Rotigotine is a non-ergolinic D 3 > D 2 > D 1 dopamine-receptor agonist for the treatment of PD using a transdermal delivery system providing stable plasma levels. We aimed to investigate the differential influence on gene expression of pulsatile l -DOPA or rotigotine versus a continuous rotigotine treatment. The gene expression profile within the nigro-striatal system of unilateral 6-hydroxydopamine-lesioned rats was assessed in order to differentiate potential changes in gene expression following the various treatment using Affymetrix microarrays and quantitative RT-PCR. The expression of 15 genes in the substantia nigra and of 11 genes in the striatum was altered under pulsatile treatments inducing dyskinetic motor response, but was unchanged under continuous rotigotine treatment that did not cause dyskinetic motor response. The route of administration of a dopaminergic drug is important for the induction or prevention of motor abnormalities and adaptive gene expressions. The decline of neurotrophin-3 expression under pulsatile administration was considered of particular importance.

Journal

Journal of Neural TransmissionSpringer Journals

Published: Dec 1, 2011

There are no references for this article.